The Case AGAINST LL-37 (Cathelicidin): Limitations and Risks

LL-37 has genuine antimicrobial and wound-healing properties supported by substantial preclinical and some clinical evidence. However, several meaningful concerns complicate the case for systemic or injectable research use of LL-37 outside controlled topical applications.

Pro-Inflammatory Dual Role

LL-37 is not simply anti-inflammatory — it is a pattern recognition peptide that can amplify or dampen immune responses depending on context. At the same concentrations that protect against bacterial LPS-driven inflammation, LL-37 can also act as an alarmin, recruiting immune cells and triggering cytokine release.

In autoimmune contexts, this is a documented problem. Research on systemic lupus erythematosus (SLE) and psoriasis has found that LL-37 forms complexes with extracellular DNA and RNA, which are then taken up by plasmacytoid dendritic cells and trigger TLR7/TLR9-mediated type I interferon production. This mechanism is implicated in the initiation and perpetuation of autoimmune flares. Patients with SLE and psoriasis show elevated LL-37 activity as a pathological feature, not a protective one.

This means systemic administration could potentially worsen or trigger autoimmune conditions in susceptible individuals — the opposite of the intended immunomodulatory effect.

Cytotoxicity at High Concentrations

LL-37's membrane-disrupting mechanism is not fully selective for bacteria. At higher concentrations, LL-37 demonstrates cytotoxicity against mammalian cells in vitro, including red blood cells (hemolysis) and certain epithelial cell lines. The therapeutic window between antimicrobial efficacy and mammalian cell toxicity narrows at systemic doses.

Topical applications can maintain high local concentrations at the wound site while limiting systemic exposure — this is why the venous leg ulcer trial used topical delivery. Injectable systemic administration does not have this advantage and the safety margin at therapeutic concentrations has not been established in humans.

Cancer Promotion Concerns

LL-37 has been shown to promote tumor growth and metastasis in several cancer models. Research has identified LL-37 overexpression in breast, ovarian, lung, and colon cancer tissue, where it appears to function as a growth factor — stimulating EGFR and other receptor tyrosine kinases on cancer cells, promoting angiogenesis, and enhancing cell migration and invasion.

This is not a theoretical concern. Multiple independent research groups have documented LL-37 as a tumor-promoting factor in epithelial cancers. For any individual with existing or undiagnosed malignancy, systemic LL-37 administration carries a meaningful oncological risk.

Clinical Data Is Primarily Topical

The Phase II clinical trial showing efficacy in venous leg ulcers used topical cream application. This is fundamentally different from systemic subcutaneous injection. Topical use confines the peptide to the local tissue environment, limits systemic absorption, and leverages the wound-healing properties without exposing the whole body to immunostimulatory concentrations.

No published human trials have evaluated systemic injectable LL-37 in healthy subjects. The extrapolation from topical wound-healing data to systemic administration is not supported by current evidence.

Short Half-Life

LL-37 is rapidly degraded by proteases in vivo. In serum, the half-life is very short — measured in minutes — which limits its pharmacological utility via systemic routes without modification. This means achieving therapeutically relevant tissue concentrations would require continuous infusion or a modified delivery system, neither of which has been validated in human research.

An Honest Assessment

LL-37's endogenous nature and wound-healing data are genuine positives. But the pro-inflammatory dual role, potential to exacerbate autoimmunity, cytotoxicity at elevated concentrations, cancer promotion data, and absence of systemic human safety data collectively mean that injectable LL-37 use carries significant unknowns that topical application data does not adequately address.

---

Disclaimer: LL-37 is a research compound not approved by the FDA for human use. This article is for informational purposes only and does not constitute medical advice.